Company Profile For AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its technology for the development and commercialization of a therapeutic iron compound to treat anemia, and imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The Company has one product candidate, Feraheme (ferumoxytol injection), and two approved products, Feridex I.V. and GastroMARK. Feraheme is being developed for use as an intravenous (IV) iron replacement therapeutic agent for the treatment of iron deficiency anemia (IDA) and as a diagnostic agent for vascular enhanced magnetic resonance imaging (MRI) to assess peripheral arterial disease (PAD). Feridex I.V., the Company’s liver contrast agent, is approved and has been sold in the United States, Europe and other countries. In November 2008, ceased manufacturing Feridex I.V. GastroMARK, its oral contrast agent used for delineating the bowel in MRI, is approved and marketed in the United States, Europe, and other countries.

BRIEF: For the nine months ended 30 September 2009, AMAG Pharmaceuticals, Inc.'s revenues totaled $4M, up from $1.4M. Net loss increased 50% to $74.9M, up from $26.3M. Revenue reflects an increase in product sales. Higher loss was offset by an increase in cost of product sales, higher research & development expenses, an increase in selling, general & administrative expenses and lower interest & dividend income, net.